NASDAQ
CRNX

Crinetics Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Crinetics Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$17.7200
Today's High:
$18.8800
Open Price:
$18.4000
52W Low:
$15.91
52W High:
$28.95
Prev. Close:
$18.5000
Volume:
239613

Company Statistics

Market Cap.:
$0.968 billion
Book Value:
7.19
Revenue TTM:
$0.005 billion
Operating Margin TTM:
-2917%
Gross Profit TTM:
$-0.083 billion
Gross Profit TTM:
$-0.083 billion
Profit Margin:
0%
Return on Assets TTM:
-26.5%
Return on Equity TTM:
-46.2%

Company Profile

Crinetics Pharmaceuticals Inc had its IPO on 2018-07-18 under the ticker symbol CRNX.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Crinetics Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of Crinetics Pharmaceuticals Inc opened at $18.4 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $17.72 - $18.88, and closed at $18.01.

This is a -2.65% slip from the previous day's closing price.

A total volume of 239,613 shares were traded at the close of the day’s session.

In the last one week, shares of Crinetics Pharmaceuticals Inc have increased by +0.06%.

Crinetics Pharmaceuticals Inc's Key Ratios

Crinetics Pharmaceuticals Inc has a market cap of $0.968 billion, indicating a price to book ratio of 2.61 and a price to sales ratio of 208.28.

In the last 12-months Crinetics Pharmaceuticals Inc’s revenue was $0.005 billion with a gross profit of $-0.083 billion and an EBITDA of $-0.135 billion. The EBITDA ratio measures Crinetics Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Crinetics Pharmaceuticals Inc’s operating margin was -2917% while its return on assets stood at -26.5% with a return of equity of -46.2%.

In Q2, Crinetics Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Crinetics Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-2.835 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Crinetics Pharmaceuticals Inc’s profitability.

Crinetics Pharmaceuticals Inc stock is trading at a EV to sales ratio of 129.5 and a EV to EBITDA ratio of -4.471. Its price to sales ratio in the trailing 12-months stood at 208.28.

Crinetics Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Crinetics Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Crinetics Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Crinetics Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Crinetics Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Crinetics Pharmaceuticals Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$18.01
52-Week High
$28.95
52-Week Low
$15.91
Analyst Target Price
$43

Crinetics Pharmaceuticals Inc stock is currently trading at $18.01 per share. It touched a 52-week high of $28.95 and a 52-week low of $28.95. Analysts tracking the stock have a 12-month average target price of $43.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Crinetics Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Crinetics Pharmaceuticals Inc is CRNX

The IPO of Crinetics Pharmaceuticals Inc took place on 2018-07-18

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$3.69
-0.03
-0.81%
$21.39
-0.96
-4.3%
$22.9
-3.28
-12.53%
$3.22
-0.3
-8.52%
$3.78
-0.1
-2.58%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
$0.02
0.01
+100%
Oi S.A (OIBR-C)
$0
0
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.

Address

10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA, US